Claims for Patent: 8,221,785

Summary for Patent: 8,221,785

Title:	Transdermal hormone delivery system: compositions and methods
Abstract:	A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.
Inventor(s):	Chien; Te-Yen (Neshanic Station, NJ)
Assignee:	Agile Therapeutics, Inc. (Princeton, NJ)
Application Number:	12/556,740
Patent Claims:	1. A transdermal contraceptive delivery system comprising a backing layer and an adhesive polymer matrix affixed to the backing layer, wherein the adhesive polymer matrix comprises: (a) an adhesive polymer comprising a polyacrylate copolymer; (b) a humectant comprising polyvinylpyrrolidone; (c) a combination of skin permeation enhancing agents consisting essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, from about 4% to about 12% dimethyl sulfoxide; from about 4.2% to about 12.6% a fatty (C.sub.8-C.sub.20) alcohol ester of lactic acid; from about 0.7% to about 2.3% lower (C.sub.1-C.sub.4) alkyl ester of lactic acid; and from about 3% to about 9% capric acid; (d) levonorgestrel; and (e) ethinyl estradiol or 17 beta-estradiol. 2. The transdermal contraceptive delivery system of claim 1, wherein the adhesive polymer is a polyacrylate adhesive copolymer that comprises a 2-ethylhexyl acrylate monomer. 3. The transdermal contraceptive delivery system of claim 2, wherein the polyacrylate adhesive copolymer further comprises about 3 to 60% w/w vinyl acetate. 4. The transdermal contraceptive delivery vehicle of claim 3, wherein the adhesive polymer matrix has a cross-sectional dimension of from about 10 to 300 microns. 5. The transdermal contraceptive delivery system of claim 1, wherein the fatty alcohol ester of lactic acid is lauryl lactate. 6. The transdermal contraceptive delivery system of claim 1, wherein the lower alkyl ester of lactic acid is ethyl lactate. 7. The transdermal contraceptive delivery system of claim 1, comprising ethinyl estradiol, wherein the ethinyl estradiol is transdermally delivered at a rate of at least about 10 mcg. but no more than 50 mcg. per day for at least a term of more than one day to about one week, and the levonorgestrel is transdermally delivered at a rate of about 30 mcg. per day for at least a term of more than one day to about one week. 8. The transdermal contraceptive delivery system of claim 1, wherein the humectant is a polyvinylpyrrolidone/vinyl acetate. 9. The transdermal contraceptive delivery system of claim 8, wherein the polyvinylpyrrolidone and the vinyl acetate are present in about equal weight percent in the polyvinylpyrrolidone/vinyl acetate mixture. 10. The transdermal contraceptive delivery system of claim 7, wherein a patch is utilized on the skin having a diameter of 7.5 cm.sup.2, 10 cm.sup.2, or 12.5 cm.sup.2. 11. A transdermal contraceptive delivery system comprising a backing layer and an adhesive polymer matrix affixed to the backing layer, wherein the adhesive polymer matrix comprises: (a) a polyacrylate adhesive copolymer that comprises a 2-ethylhexyl acrylate monomer and about 3 to about 60% w/w vinyl acetate; (b) a humectant comprising a polyvinylpyrrolidone/vinyl acetate copolymer; (c) a combination of skin permeation enhancing agents comprising between about 12% and about 36% by weight of the adhesive polymer matrix and consisting essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, from about 4% to about 12% dimethyl sulfoxide; from about 4.2% to about 12.6% lauryl lactate; from about 0.7% to about 2.3% ethyl lactate; and from about 3% to about 9% capric acid; (d) levonorgestrel; and (e) ethinyl estradiol. 12. The transdermal delivery system of claim 11, wherein the combination of skin permeation enhancing agents is between about 18% and about 30% by weight of the adhesive polymer matrix and consists essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, from about 5% to about 11% dimethyl sulfoxide; from about 5.2% to about 11.6% lauryl lactate; from about 1% to about 2% ethyl lactate; and from about 4% to about 8% capric acid. 13. The transdermal delivery system of claim 12, wherein the combination of skin permeation enhancing agents is between about 21% and about 27% by weight of the adhesive polymer matrix and consists essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, from about 6% to about 10% dimethyl sulfoxide; from about 6.2% to about 10.6% lauryl lactate; from about 1.2% to about 1.8% ethyl lactate; and from about 5% to about 7% capric acid. 14. A transdermal contraceptive delivery system comprising a backing layer and an adhesive polymer matrix affixed to the backing layer, wherein the adhesive polymer matrix comprises: (a) a polyacrylate adhesive copolymer that comprises a 2-ethylhexyl acrylate monomer and about 3 to about 60% w/w vinyl acetate; (b) a humectant comprising a polyvinylpyrrolidone/vinyl acetate copolymer having a molecular weight of at least about 50,000 and comprising about equal weight percents of polyvinylporrolidone and vinyl acetate; (c) a combination of skin permeation enhancing agents comprising between about 21% and about 27% by weight of the adhesive polymer matrix and consisting essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, from about 6% to about 10% dimethyl sulfoxide; from about 6.2% to about 10.6% lauryl lactate; from about 1.2% to about 1.8% ethyl lactate; and from about 5% to about 7% capric acid; (d) levonorgestrel; and (e) ethinyl estradiol. 15. The transdermal contraceptive delivery system of claim 14, wherein the combination of skin permeation enhancing agents consists essentially of, on a final percentage by weight of the adhesive polymer matrix after fabrication of the system, about 8% dimethyl sulfoxide, about 8.4% lauryl lactate, about 1.5% ethyl lactate and about 6% capric acid.